TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,727,074 | -35.4% | 4,667,458 | +10.9% | 0.00% | -50.0% |
| Q2 2023 | $64,623,852 | -27.9% | 4,207,282 | +5.6% | 0.00% | 0.0% |
| Q1 2023 | $89,613,520 | +21.2% | 3,984,594 | +13.3% | 0.00% | 0.0% |
| Q4 2022 | $73,929,829 | -11.3% | 3,515,446 | +4.0% | 0.00% | 0.0% |
| Q3 2022 | $83,323,000 | +3.2% | 3,381,610 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $80,707,000 | -18.6% | 3,330,819 | -13.4% | 0.00% | 0.0% |
| Q1 2022 | $99,152,000 | -17.7% | 3,847,535 | -0.9% | 0.00% | -33.3% |
| Q4 2021 | $120,462,000 | +28.5% | 3,880,873 | +0.4% | 0.00% | +50.0% |
| Q3 2021 | $93,738,000 | +67.5% | 3,865,481 | +0.8% | 0.00% | +100.0% |
| Q2 2021 | $55,949,000 | -44.0% | 3,834,756 | -4.2% | 0.00% | -66.7% |
| Q1 2021 | $99,920,000 | +7.7% | 4,001,588 | +17.5% | 0.00% | 0.0% |
| Q4 2020 | $92,788,000 | – | 3,404,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |